Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Boland

Showing results (421-430 of 571) with videos related to

Pageof 58
Sort By:
Cancer Chemotherapy and Pharmacology|July 29, 2022
A dose regimen-finding study to evaluate the safety, tolerability, pharmacokinetics, and activity of oratecan in subjects with advanced malignanciesPatrick M Boland, Christos Fountzilas, Marwan Fakih, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2021
ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel AdenocarcinomaKatrina S Pedersen, Nathan R Foster, Michael J Overman, et al.
Journal of the International Neuropsychological Society : JINS|August 18, 2025
Differences in neuropsychological performance across clinical variants of progressive supranuclear palsyElizabeth A Boots, Stephen D Weigand, Nha Trang Thu Pham, et al.
Nature Communications|October 16, 2021
Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanomaKuang Du, Shiyou Wei, Zhi Wei, et al.
Molecular Therapy. Oncology|March 4, 2025
Use of patient-derived organotypic tumor spheroids for testing of viral vector gene therapy in combination with checkpoint blockadeAna Carolina M Domingues, Soraia B de Oliveira, Nayara G Tessarollo, et al.
Cancer Medicine|December 4, 2025
Real-World Outcomes of Adjuvant Therapy in Stage III Melanoma and the Impact of Somatic MutationsDerek Effiom, Tyler Aprati, Anastasios Karneris, et al.
Journal of the American Academy of Dermatology|March 21, 2023
Increased risk of cutaneous immune-related adverse events in patients treated with talimogene laherparepvec and immune checkpoint inhibitors: A multi-hospital cohort studyBonnie W Leung, Guihong Wan, Nga Nguyen, et al.
American Journal of Clinical Oncology|March 18, 2016
Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by ResectionPatrick M Boland, Joshua E Meyer, Adam C Berger, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 15, 2013
Noninvasive characterization of the histopathologic features of pulmonary nodules of the lung adenocarcinoma spectrum using computer-aided nodule assessment and risk yield (CANARY)--a pilot studyFabien Maldonado, Jennifer M Boland, Sushravya Raghunath, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 24, 2018
Comparison of Risk Stratification Models to Predict Recurrence and Survival in Pleuropulmonary Solitary Fibrous TumorJanani S Reisenauer, Wadad Mneimneh, Sarah Jenkins, et al.
Pageof 58

Showing results (421-430 of 571) with videos related to

Sort By:
Pageof 58
Cancer Chemotherapy and Pharmacology|July 29, 2022
A dose regimen-finding study to evaluate the safety, tolerability, pharmacokinetics, and activity of oratecan in subjects with advanced malignanciesPatrick M Boland, Christos Fountzilas, Marwan Fakih, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2021
ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel AdenocarcinomaKatrina S Pedersen, Nathan R Foster, Michael J Overman, et al.
Journal of the International Neuropsychological Society : JINS|August 18, 2025
Differences in neuropsychological performance across clinical variants of progressive supranuclear palsyElizabeth A Boots, Stephen D Weigand, Nha Trang Thu Pham, et al.
Nature Communications|October 16, 2021
Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanomaKuang Du, Shiyou Wei, Zhi Wei, et al.
Molecular Therapy. Oncology|March 4, 2025
Use of patient-derived organotypic tumor spheroids for testing of viral vector gene therapy in combination with checkpoint blockadeAna Carolina M Domingues, Soraia B de Oliveira, Nayara G Tessarollo, et al.
Cancer Medicine|December 4, 2025
Real-World Outcomes of Adjuvant Therapy in Stage III Melanoma and the Impact of Somatic MutationsDerek Effiom, Tyler Aprati, Anastasios Karneris, et al.
Journal of the American Academy of Dermatology|March 21, 2023
Increased risk of cutaneous immune-related adverse events in patients treated with talimogene laherparepvec and immune checkpoint inhibitors: A multi-hospital cohort studyBonnie W Leung, Guihong Wan, Nga Nguyen, et al.
American Journal of Clinical Oncology|March 18, 2016
Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by ResectionPatrick M Boland, Joshua E Meyer, Adam C Berger, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 15, 2013
Noninvasive characterization of the histopathologic features of pulmonary nodules of the lung adenocarcinoma spectrum using computer-aided nodule assessment and risk yield (CANARY)--a pilot studyFabien Maldonado, Jennifer M Boland, Sushravya Raghunath, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 24, 2018
Comparison of Risk Stratification Models to Predict Recurrence and Survival in Pleuropulmonary Solitary Fibrous TumorJanani S Reisenauer, Wadad Mneimneh, Sarah Jenkins, et al.
Pageof 58